Heart Failure and Drug Therapies: A Metabolic Review.

Frank Yu, Bianca McLean, Mitesh Badiwala, Filio Billia

Journal: International journal of molecular sciences 2022;23(6):2960

PMID: 35328390

Abstract

["Cardiovascular disease is the leading cause of mortality globally with at least 26 million people worldwide living with heart failure (HF). Metabolism has been an active area of investigation in the setting of HF since the heart demands a high rate of ATP turnover to maintain homeostasis. With the advent of -omic technologies, specifically metabolomics and lipidomics, HF pathologies have been better characterized with unbiased and holistic approaches. These techniques have identified novel pathways in our understanding of progression of HF and potential points of intervention. Furthermore, sodium-glucose transport protein 2 inhibitors, a drug that has changed the dogma of HF treatment, has one of the strongest types of evidence for a potential metabolic mechanism of action. This review will highlight cardiac metabolism in both the healthy and failing heart and then discuss the metabolic effects of heart failure drugs."]
Address: Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, ON M5G 2C4, Canada.; Ted Rogers Centre for Heart Research, Toronto, ON M5G 1X8, Canada.; Degroote School of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada.; Toronto General Hospital Research Institute, Toronto, ON M5G 2C4, Canada.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.